Cardiometabolic
Addressing gaps in care and insights
Cardiometabolic conditions affect millions of patients and many of those conditions are associated with high mortality rates. Yet, despite development of new treatments, major advancements in many ways lag behind those for oncology and other chronic medical condition areas. And, high quality research-driven insights to enable market adoption, understand safety and effectiveness profiles, broaden payer coverage, and increase access to care are lacking or have been difficult to attain.
Cardiometabolic conditions are complex. Accessing data shouldn’t be.
Understanding the complexities of these diseases, how they relate to other comorbid conditions, and their impact on different patient populations requires a dynamic new approach to cardiometabolic data curation.
Meet the OM1 cardiovascular and metabolic datasets
A comprehensive view of the patient journey from clinical development to the clinic
Bringing new treatments to market and delivering more precise care is challenging enough. Finding the data to empower your programs shouldn’t be. That’s why OM1 built cardiovascular and metabolic datasets in the U.S — rich with longitudinal clinical data and ready for addressing your most urgent questions.
1,200+*Cardiologists 200+Cardiology practices & IDNs *These numbers reflect cardiology specialists and practices and do not include other metabolic specialists and care providers. Contact OM1 for more details on those areas. |
Cardiometabolic Conditions• Amyloidosis |
Sample conditions*
Every condition presents its own unique challenges and opportunities. Select one of our sample datasets above to explore some of the features.
Atrial fibrillation patients with deep clinical data
6.3 yrs
Mean follow-up
Heart failure patients with deep clinical data
7.3 yrs
Mean follow-up
NASH patients with deep clinical data including many with liver biopsy results
7.0 yrs
Mean follow-up
*Data counts as of Q1 2022 ©OM1 Cardiometabolic Specialty Area
From evidence to insights
USE CASE
Addressing an unmet need in HF
Rapidly quantify and characterize patients not eligible for revascularization, with Ischemic Chronic HF and reduced LVEF
LEARN MORE
USE CASE
Comparative effectiveness analysis of the choice of non-vitamin K oral anticoagulant (NOAC) as first line therapy for patients with non-valvular atrial fibrillation (NVAF)
Understanding the real-world comparative effectiveness of NOACs is challenging due to bias arising from clinical practice (confounding by indication, specifically).
LEARN MORE
USE CASE
Identify under-and un-diagnosed NASH patients with deep clinical data and advanced AI
Identification of both probable and confirmed non-alcoholic fatty liver disease (NAFLD) and NASH is hampered by asymptomatic disease, under-diagnosis in routine care, lack of condition-specific treatments and poor billing code specificity.
LEARN MORE
How we can help
Our specialized data and tools provide access to longitudinal patient journeys, and critical outcomes and endpoints, to enable rapid and more in-depth analyses.
NASH Disease Progression
Fully utilize deep, clinical RWD to more efficiently design and conduct clinical trials such as seeing where unmet needs are greatest or determining which groups the protocol should be designed to enroll.
Measure key safety outcomes of interest and support regulatory requirements, such as monitoring and comparing the real-world safety profiles for patients on PCKS9 inhibitors.
Align with real world-based patient behaviors to measure adherence to novel treatment approaches, such as for obesity.
Develop sound evidence for payers through deep clinical and linked claims data for a more complete view of clinical outcomes and utilization. For example, to assess the cost effectiveness of early treatment interventions for AFib.
RWD can help guide planning, forecasting, and improving brand performance, such as understanding the size of the market by segment in patient subtypes that are best aligned with a brand’s positioning.
Meet our cardiometabolic expert
Gary Curhan, MD, ScD is the Chief Medical Officer of OM1, Inc. He is a practicing nephrologist in Boston. Dr. Curhan has published widely on the epidemiology of many medical conditions including cardiovascular disease, hypertension, kidney stones, gout, hearing loss and others. His research in several large cohort studies, including the Nurses’ Health Studies and the Health Professionals Follow-Up Study, focuses on the prevention of common diseases by investigating scientifically and clinically important questions and exploring the role of modifiable factors and has been supported continuously for over 25 years by the National Institutes of Health. He was the Editor-in-Chief of the Clinical Journal of the American Society of Nephrology, a leading nephrology journal. He has served on many national and international advisory committees, including the National Institutes of Health. He has mentored numerous individuals, many of whom now hold leadership positions at major academic institutions and public companies.
Dr. Curhan is a graduate of Brown University, Harvard Medical School and Harvard School of Public Health. Prior to joining OM1, he was a Professor of Medicine at Harvard Medical School and Professor of Epidemiology at Harvard School of Public Health.
Award-Winning Research Team
Our team of award-winning researchers have authored hundreds of publications, including scientific posters, articles in peer-reviewed journals, white papers, and books.